We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer.
- Authors
Stevenson, J P; Redlinger, M; Kluijtmans, L A; Sun, W; Algazy, K; Giantonio, B; Haller, D G; Hardy, C; Whitehead, A S; O'Dwyer, P J
- Abstract
Irinotecan and raltitrexed display schedule-dependent synergy in vitro, which supports the clinical investigation of the combination. Functional polymorphisms of the methylenetetrahydrofolate reductase (MTHFR) gene result in intracellular redistribution of folate derivatives, which may affect raltitrexed-associated cytotoxicity.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Vol 19, Issue 20, p4081
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2001.19.20.4081